

**Brilliant Violet 711™ anti-human CD10**

**Catalog # / Size:** 2161125 / 25 tests  
2161130 / 100 tests

**Clone:** HI10a

**Isotype:** Mouse IgG1, κ


**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 711™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 711™ and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

**Workshop Number:** V CD10.7

**Concentration:** 0.2



Human peripheral blood granulocytes were stained with CD10 (clone HI10a) Brilliant Violet 711™ (filled histogram) or mouse IgG1, κ Brilliant Violet 711™ isotype control (open histogram).

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 711™ excites at 405 nm and emits at 711 nm. The bandpass filter 710/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 711™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application Notes:** Additional reported (for the relevant formats) applications include: immunohistochemistry<sup>6</sup>.

**Application****References:**

1. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
  2. Barclay N, *et al.* 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
  3. Schlossman S, *et al.* Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  4. Denny MF, *et al.* 2010. *J. Immunol.* 184:3284. [PubMed](#)
  5. Yoshino N, *et al.* 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
  6. Dall'Era MA, *et al.* 2007. *BMC Urol.* 7:3. (IHC)
- 

**Description:**

CD10 is a 100 kD neutral endopeptidase and a member of the metalloprotease family. It is a type II transmembrane protein also known as common acute lymphoblastic leukemia antigen (CALLA), enkephalinase, and neprilysin. CD10 is expressed on B cell precursors, T cell precursors, and neutrophils. CD10 is involved in B cell development and has been shown to bind opioid enkephalins, bradykinin, angiotensins I and II, and other biologically active peptides.

**Antigen****References:**

1. Shipp M, *et al.* 1993. *Blood* 82:1052.
2. Lu B, *et al.* 1995. *J. Exp. Med.* 181:2271.